BioCentury | Apr 20, 2020
Finance

French VC Sofinnova expanding start-up ecosystem in Italy with new local fund’s first investments

...fund’s first three deals are investments in epigenetics company Epsilen Bio, rare dermatological diseases play PinCell...
BioCentury | Mar 19, 2019
Distillery Therapeutics

Inhibiting FASL for ischemic stroke

...a control IgG. Next steps could include testing the anti-FASL mAb in other stroke models. PinCell s.r.l....
BioCentury | Dec 13, 2017
Distillery Therapeutics

Cancer

...Next steps could include identifying and testing other FASL inhibitors in additional models of cancer. PinCell s.r.l....
BioCentury | Apr 23, 2012
Clinical News

PC111 regulatory update

...The European Commission granted Orphan Drug designation for PinCell's PC111 to treat pemphigus. The human mAb...
...testing. The company plans to start a Phase I trial in the indication in 2Q13. PinCell s.r.l....
Items per page:
1 - 4 of 4
BioCentury | Apr 20, 2020
Finance

French VC Sofinnova expanding start-up ecosystem in Italy with new local fund’s first investments

...fund’s first three deals are investments in epigenetics company Epsilen Bio, rare dermatological diseases play PinCell...
BioCentury | Mar 19, 2019
Distillery Therapeutics

Inhibiting FASL for ischemic stroke

...a control IgG. Next steps could include testing the anti-FASL mAb in other stroke models. PinCell s.r.l....
BioCentury | Dec 13, 2017
Distillery Therapeutics

Cancer

...Next steps could include identifying and testing other FASL inhibitors in additional models of cancer. PinCell s.r.l....
BioCentury | Apr 23, 2012
Clinical News

PC111 regulatory update

...The European Commission granted Orphan Drug designation for PinCell's PC111 to treat pemphigus. The human mAb...
...testing. The company plans to start a Phase I trial in the indication in 2Q13. PinCell s.r.l....
Items per page:
1 - 4 of 4